<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523614</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2007_02</org_study_id>
    <nct_id>NCT00523614</nct_id>
  </id_info>
  <brief_title>Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism</brief_title>
  <official_title>Use of OCs Containing Dienogest and Risk of Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral
      contraceptives with non-use, focusing specifically on Valette® compared to other users of low
      estrogen dose combined oral contraceptives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a population-based case-control study in Germany.

      Cases are women who are between 15 and 49 years old with a diagnosis of venous
      thromboembolism (VTE). The VTE is diagnosed in Germany between January 2002 und December
      2007.

      Controls are women who are between 15 and 49 years old without a VTE diagnosis. About 4
      controls matched by year of birth and region will be allocated to each case.

      Both cases and controls will receive a similar self-administered questionnaire except of some
      case-specific questions which are not applicable for the controls.

      Study participants will be asked for their informed consent. Data confidentiality will be
      ensured by the Berlin Center for Epidemiology and Health Research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC)</measure>
    <time_frame>01/2002 - 01/2008</time_frame>
    <description>The time frame is the time when venous thromboembolism (VTE) was diagnosed in the cases group. VTE includes deep venous thrombosis and pulmonary embolism. These clinical endpoints were established by magnetic resonance imaging, spiral computer tomography, duplex sonography, and lung scintigraphy.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3400</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>1: Cases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cases: women between 15 and 49 years old with a VTE diagnosed in Germany between 2002 and
        2007

        Controls: population sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cases: women with a venous thromboembolism who are between 15 and 49 years old

          -  control: women without a venous thromboembolism diagnosis who are between 15 and 49
             years old

        Exclusion Criteria:

          -  women outside the defined age range

          -  women with severe language problems

          -  women who are not willing to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen C Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemilogy and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <results_first_submitted>June 22, 2009</results_first_submitted>
  <results_first_submitted_qc>October 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2009</results_first_posted>
  <last_update_submitted>March 19, 2010</last_update_submitted>
  <last_update_submitted_qc>March 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Juergen C Dinger, MD, PhD, Principal Investigator</name_title>
    <organization>Center for Epidemiology and Health Research, Germany</organization>
  </responsible_party>
  <keyword>venous thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Identification started in spring 2007 and ended in January 2008. Cases (VTE=venous thromboembolism diagnosed in Germany between 01/2002 and 01/2008) were identified by primary care physicians. For each case 4 community-based controls (no VTE between 01/2002 and 01/2008) were selected.The controls were identified from randomly selected households.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cases</title>
          <description>Women with a venous thromboembolism who are between 15 and 49 years old</description>
        </group>
        <group group_id="P2">
          <title>Controls</title>
          <description>Women without a venous thromboembolism diagnosis who are between 15 and 49 years old</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="680">As this is a case-control study the categories &quot;started&quot; and &quot;completed&quot; are not really applicable.</participants>
                <participants group_id="P2" count="2720">As this is a case-control study the categories &quot;started&quot; and &quot;completed&quot; are not really applicable.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="680">As this is a case-control study the categories &quot;started&quot; and &quot;completed&quot; are not really applicable.</participants>
                <participants group_id="P2" count="2720">As this is a case-control study the categories &quot;started&quot; and &quot;completed&quot; are not really applicable.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cases</title>
          <description>Women with a venous thromboembolism who are between 15 and 49 years old</description>
        </group>
        <group group_id="B2">
          <title>Controls</title>
          <description>Women without a venous thromboembolism diagnosis who are between 15 and 49 years old</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="680"/>
            <count group_id="B2" value="2720"/>
            <count group_id="B3" value="3400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="665"/>
                    <measurement group_id="B2" value="2660"/>
                    <measurement group_id="B3" value="3325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="9.0"/>
                    <measurement group_id="B2" value="36.1" spread="9.0"/>
                    <measurement group_id="B3" value="36.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="680"/>
                    <measurement group_id="B2" value="2720"/>
                    <measurement group_id="B3" value="3400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="680"/>
                    <measurement group_id="B2" value="2720"/>
                    <measurement group_id="B3" value="3400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC)</title>
        <description>The time frame is the time when venous thromboembolism (VTE) was diagnosed in the cases group. VTE includes deep venous thrombosis and pulmonary embolism. These clinical endpoints were established by magnetic resonance imaging, spiral computer tomography, duplex sonography, and lung scintigraphy.</description>
        <time_frame>01/2002 - 01/2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Women with a venous thromboembolism who are between 15 and 49 years old</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Women without a venous thromboembolism who are between 15 and 49 years old</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC)</title>
          <description>The time frame is the time when venous thromboembolism (VTE) was diagnosed in the cases group. VTE includes deep venous thrombosis and pulmonary embolism. These clinical endpoints were established by magnetic resonance imaging, spiral computer tomography, duplex sonography, and lung scintigraphy.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="680"/>
                <count group_id="O2" value="2720"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Exposed DNG/EE COC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposed low-dose COC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: OR ≥ 2 (VTE of DNG/EE vs. other low-dose COC)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Size of the study adapted to the use of DNG/EE in female fertile age. Market share of DNG/EE of 13% in Germany. Assuming that 30% of women in the fertile age range were current users of OCs, a prevalence of current use of DNG/EE of about 4% was estimated.
Based on these data the number of cases needed to exclude a twofold increased VTE risk was estimated at about 500-700 cases (based on four controls per case).</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cases</title>
          <description>Women with a venous thromboembolism who are between 15 and 49 years old</description>
        </group>
        <group group_id="E2">
          <title>Controls</title>
          <description>Women without a venous thromboembolism diagnosis who are between 15 and 49 years old</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="680"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2720"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="680"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2720"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is an observational study. The possibility of bias and residual confounding cannot be entirely eliminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Juergen Dinger, MD, PhD, Principal Investigator</name_or_title>
      <organization>Berlin Center for Epidemiology and Health Research, Germany</organization>
      <phone>+49 30 94510145</phone>
      <email>dinger@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

